Alert: Packaging World now enhanced for the iPad and iPhone. Watch a quick video preview
 
Download Download this free, 150-page Pharmaceutical Serialization Playbook jam-packed with strategies for success and pitfalls to avoid.  Learn more >>
Article |

Open up and say 'Ah' (sidebar)

FDA sticks its nose into antihistamines
Print Reprint
FILED IN:  Machinery  > Labeling
     

Packaging of over-the-counter antihistamines is on a second front burner in Washington too. After about 15 years of regulatory noodling the FDA will decide whether label claims asserting “For relief of cold & allergy symptoms” can remain on antihistamine packages. The label copy enumerates the symptoms as “nasal congestion sneezing runny nose & itchy watery eyes.” Aside from package copy today’s product manufacturers display copy via print advertising media etc. Dimetapp® seems to be among the most aggressive advertising its Cold & Cough Liqui-Gels® as giving “Fast” relief. No other product appears to make the “Fast” claim. Sudafed® on the other hand says nothing about offering relief while it simply lists the symptoms the product helps. Benadryl Allergy® says “For allergy relief.” Products can make those label claims today for one of two reasons. Many products had their active ingredients listed in a “tentative” monograph published by the FDA in 1985. That monograph said that all active ingredients—and they were specifically named—contained in what are called Category 1 antihistamines have the same relief of cold symptoms as chlorpheniramine maleate another Category 1 active for which two manufacturers provided supporting clinical evidence. There was no supporting data for the other Category 1 actives. The FDA was essentially taking a scientific leap of faith. Products that came on the OTC market after 1985 may have had their active ingredients approved originally as prescription medications. The FDA may have approved the “For relief of cold...” claim based on data the manufacturer submitted as part of the new drug application (NDA). The knees of manufacturers of the pre-1985 OTC antihistamines are knocking the loudest. Here’s why. In 1995 FDA’s own New Drug Advisory Committee said that only two Category 1 actives—chlorpheniramine maleate and doxylamine succinate—have clear data that backs up their claim. The Advisory Committee argued that data could not be extrapolated to other Category 1 actives. Among major products Contact® by SmithKline Beecham Chlor-Trimeton® from Schering-Plough and Warner-Lambert’s Sudafed® contain chlorpheniramine malate. Chlor-Trimeton boasts on its outer carton that it contains chlorpheniramine malate. But these also contain other Category 1 actives besides the two approved by the Advisory Committee in 1995. Normally the FDA accepts the advice of its advisory committees. This time it appears as if it will reject that advice. One FDA official who is working on the issue acknowledges that the antihistamine labeling issue “has two sides” and that it is “controversial.” That explains why the FDA has waited five years before it may countermand the recommendation of its own advisory committee. Kay Freeman an FDA official says that clinical evidence establishing the effectiveness of some active ingredients has become available since 1995. The FDA is making this data available for the first time. But Freeman says the FDA will only present the data to the NDAC. Patrice Wright director of pharmacology and toxicology for the Consumer Healthcare Products Assn. says that OTC antihistamines can make the “For relief of colds...” claim if data exists to back up that contention. “But they understand that the claims have not yet been formally blessed by the FDA” she adds.

See the main story that goes with this sidebar: Open up and say ‘Ah’

Comments(0)

Add new comment

E-BOOK SPECIAL REPORT
42 Best Package Designs
Sign up to receive timely updates from our editors and download this e-book consisting of our editors' picks of most notable package designs. Updated for 2014!
x

Newsletters

Don't miss intelligence crucial to your job and business!
Click on any newsletter to view a sample. Enter your email address below to sign up!
GENERAL INTEREST
PACKAGE DESIGN/DEVELOPMENT
Each newsletter ranges in frequency from once per month to a few times per month at most.